RTP Mobile Logo
Investigator Perspectives on Emerging Concepts in the Management of Genitourinary Cancers (Video Program)
Released April 2016

Featuring perspectives from Drs Charles G Drake, Daniel J George, Leonard G Gomella and Daniel P Petrylak. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, urologists and radiation oncologists.

    Cancers of the genitourinary (GU) system affect hundreds of thousands of individuals within the United States each year and account for almost 30% of new cancer diagnoses. Although GU cancers are a diverse array of distinct diseases, tumors of the bladder, kidney (and renal pelvis) and prostate are among the most prevalent and are therefore the topic of extensive ongoing research. As such, the clinical management of these diseases is currently in a state of evolution, necessitating rapid and consistent access to learning opportunities for clinicians who provide care for these patients. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, urologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with GU cancers.


    • Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with castration-resistant prostate cancer (PC), and use this information to guide therapeutic decision-making.
    • Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.
    • Develop an evidence-based approach to the sequencing of systemic therapies for patients with advanced renal cell carcinoma (RCC), incorporating tyrosine kinase inhibitors, anti-VEGF antibodies and mTOR inhibitors.
    • Recognize toxicities attributable to diverse molecular-targeted treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies in patients with metastatic RCC and bladder cancer.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    It is the policy of Research To Practice and Yale Continuing Medical Education to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Yale Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles G Drake, MD, PhD
    Co-Director, Multi-D Prostate Cancer Clinic
    Co-Director, Division of Immunology
    Professor of Oncology, Urology and Immunology
    Johns Hopkins Sidney Kimmel Cancer Center
    Baltimore, Maryland

    Consulting Agreements: Amplimmune Inc, Bristol-Myers Squibb Company, Compugen, Dendreon Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, ImmuneXcite Inc, ImmuNext Inc, Novartis Pharmaceuticals Corporation, Potenza Therapeutics, Roche Laboratories Inc, Sanofi; Patents: Amplimmune Inc, Bristol-Myers Squibb Company, Potenza Therapeutics; Stock Ownership: Compugen, ImmuneXcite Inc, ImmuNext Inc.

    Daniel J George, MD
    Professor of Medicine and Surgery
    Director of Genitourinary Oncology Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Dendreon Pharmaceuticals Inc, GlaxoSmithKline, Pfizer Inc, Sanofi, Viamet Pharmaceuticals Inc; Consulting Agreements: Acceleron Pharma, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi, Viamet Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi, Takeda Oncology, Viamet Pharmaceuticals Inc; Speakers Bureau: Dendreon Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    Leonard G Gomella, MD
    The Bernard W Godwin Professor of Prostate Cancer
    Chairman, Department of Urology
    Associate Director, Jefferson Sidney Kimmel Cancer Center
    Clinical Director, Jefferson Sidney Kimmel Cancer Center Network
    Editor-in-Chief, Canadian Journal of Urology
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Merck; Contracted Research: Astellas Pharma Global Development Inc.

    Daniel P Petrylak, MD (Co-Chair)
    Professor of Medicine
    Director, Prostate and GU Medical Oncology
    Co-Director, Signal Transduction Program
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi; Grant Support: Dendreon Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Genentech BioOncology, Janssen Biotech Inc, Merck and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Bladder cancer
HER2-positive bladder cancer (Dr Petrylak)
Neoadjuvant chemotherapy and surgical options in muscle-invasive bladder cancer (Dr Gomella)
Blue light cystoscopy in the initial diagnosis of bladder cancer (Dr Gomella)
Atezolizumab in advanced bladder cancer (Dr Petrylak)
Other checkpoint inhibitors in bladder cancer (Dr Petrylak)
Nonresearch use of checkpoint inhibitors in bladder cancer (Dr Petrylak)
Prostate cancer
First-line therapy for men with metastatic castration-resistant prostate cancer (mCRPC) (Dr George)
Tolerability of second-generation endocrine agents in prostate cancer (Dr Petrylak)
AR-V7 status and response to chemotherapy and/or endocrine therapy in mCRPC (Dr Petrylak)
Sequencing abiraterone and enzalutamide in mCRPC (Dr George)
STRIVE trial: Enzalutamide versus bicalutamide for men with nonmetastatic or metastatic CRPC (Dr George)
Use of corticosteroids with abiraterone; fatigue with enzalutamide (Dr Gomella)
Renal cell carcinoma
Sequencing and comparative tolerability of pazopanib and sunitinib for patients with metastatic renal cell carcinoma (mRCC) (Dr George)
Lenvatinib and everolimus compared to either agent alone for mRCC (Dr George)
Everolimus as second-line treatment for mRCC (Dr Petrylak)
Case discussion: A 60-year-old man with metastatic non-clear cell RCC treated with everolimus (Dr Gomella)
Checkpoint inhibitors (Dr Drake)
Anti-PD-1 and CTLA-4 combinations
Duration of anti-PD-1/PD-L1 therapy for patients responding to treatment
Correlation between PD-L1 expression and response to checkpoint blockade
Checkpoint blockade in patients with prior autoimmune disorders